Research Topics
| David L PorterSummaryAffiliation: University of Pennsylvania Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor ProgramChatchada Karanes
City of Hope National Medical Center, Duarte, California, USA
Biol Blood Marrow Transplant 14:8-15. 2008..Correspondingly, survival within each disease category has improved. Particularly gratifying are the results in severe aplastic anemia (AA) where 2-year survival has doubled in just 10 years...- Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversiesDavid L Porter
Division of Hematology Oncology, Blood and Marrow Transplant Program, University of Pennsylvania Medical Center, Philadelphia, PA, USA
Hematology Am Soc Hematol Educ Program 2011:292-8. 2011.... 
Donor leukocyte infusions in myeloid malignancies: new strategiesDavid L Porter
University of Pennsylvania Medical Center, 16 Penn Tower, 3400 Spruce St, Philadelphia, PA 19104, USA
Best Pract Res Clin Haematol 19:737-55. 2006..Although many issues remain unsettled, the potential to harness the graft-versus-leukemia activity of allogeneic donor cells provides a powerful new paradigm for the immunotherapy of cancer...
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemiaDavid L Porter
Abramson Cancer Center, and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
N Engl J Med 365:725-33. 2011..Remission was ongoing 10 months after treatment. Hypogammaglobulinemia was an expected chronic toxic effect...- T-cell reconstitution and expansion after hematopoietic stem cell transplantation: 'T' it up!D L Porter
Department of Medicine, Hematology Oncology Division, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA
Bone Marrow Transplant 35:935-42. 2005..These data all support the premise that adoptive therapy can accelerate reconstitution of cellular immunity with enhanced antitumor effects following SCT... - Allogeneic cell therapy for patients who relapse after autologous stem cell transplantationD L Porter
Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Medical Center, Philadelphia 19104, USA
Biol Blood Marrow Transplant 7:230-8. 2001..Most patients developed donor chimerism with minimal conditioning. Alternative prophylactic regimens that control GVHD while maintaining GVT are needed to improve outcomes in these heavily pretreated patients... - A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulationDavid L Porter
Stem Cell Transplant Program, Division of Hematology Oncology, 16 Penn Tower, 3400 Spruce St, Philadelphia, PA 19104, USA
Blood 107:1325-31. 2006..Adoptive transfer of costimulated activated allogeneic T cells is feasible, does not result in excessive GVHD, and may contribute to durable remissions in diseases where conventional DLI has been disappointing... - NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell TransplantationDavid L Porter
University of Pennsylvania Medical Center, Philadelphia, 19104, USA
Biol Blood Marrow Transplant 16:1467-503. 2010..In addition, recommendations are provided for specific areas of research necessary in the treatment of relapse after alloHSCT... - A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemiaAlexander E Perl
Hematologic Malignancies Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA
Clin Cancer Res 15:6732-9. 2009..We sought to determine the safety and describe the toxicity of this approach by adding the mTOR inhibitor, sirolimus (rapamycin), to intensive AML induction chemotherapy... - Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantationGinna G Laport
Translational Research Program, Abramsonm Family Cancer Research Institute, University of Pennsylvania School of Medicine, 421 Curie Blvd, Philadelphia, PA 19104-6160, USA
Blood 102:2004-13. 2003.... - Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell supportDan T Vogl
Bone Marrow and Stem Cell Transplant Program, Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
Am J Hematol 82:1071-5. 2007..Future trials comparing induction therapies should examine progression-free and overall survival after transplant to confirm this benefit... - Blockade of lymphocyte chemotaxis in visceral graft-versus-host diseaseRan Reshef
Abramson Cancer Center and the Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
N Engl J Med 367:135-45. 2012..The chemokine receptor CCR5 appears to play a role in alloreactivity. We tested whether CCR5 blockade would be safe and limit GVHD in humans... - T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemiaMichael Kalos
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA
Sci Transl Med 3:95ra73. 2011.... - A predictive model for the detection of tumor lysis syndrome during AML induction therapyAnthony R Mato
Hematologic Malignancies Program, Division of Hematology and Oncology, Department of Internal Medicine, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
Leuk Lymphoma 47:877-83. 2006..This analysis may lay the groundwork for the development of the first evidence-based guidelines for TLS monitoring and management in this patient population... - Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversiesSteven C Goldstein
Division of Hematology Oncology BMT, Abramson Cancer Center, University of Pennsylvania Medical Center, 2 Perelman, 3400 Civic Center Blvd, Philadelphia, PA, USA
Expert Rev Hematol 3:301-14. 2010.... - Serum protein electrophoresis abnormalities in adult solid organ transplant patients with post-transplant lymphoproliferative disorderDonald E Tsai
Hematologic Malignancies Program, University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA
Clin Transplant 19:644-52. 2005..68 wk, p = 0.003). Persistence of MG after complete response of the PTLD did not predict relapse. There is a high incidence of MG and gammaglobulin abnormalities in patients with PTLD... - Leukemic gingival infiltrate as an indicator of chemotherapeutic failure following monoclonal antibody therapy: a case reportThomas P Sollecito
Division of Oral Medicine, School of Dental Medicine, 4001 Spruce Street, University of Pennsylvania, Philadelphia, PA 19104, USA
Spec Care Dentist 23:108-10. 2003..This case history raises the possibility that leukemic sanctuary sites may exist, and that monoclonal antibody therapy may have sub-optimal activity in non-medullary sites of disease... - Donor leukocyte infusions after unrelated donor hematopoietic stem cell transplantationAlison W Loren
Stem Cell Transplant Program and Hematology-Oncology Division, Abramson Cancer Center, University of Pennsylvania, Philadelphia, 19104, USA
Curr Opin Oncol 18:107-14. 2006..We discuss anticipated outcomes and identify areas under active investigation in both ablative and nonmyeloablative unrelated-donor stem cell transplantation... - Impact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantationAlison W Loren
Stem Cell Transplant Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Biol Blood Marrow Transplant 12:758-69. 2006..Until the effects of pregnancy on the maternal immune system are better understood, it is appropriate whenever possible to avoid parous female donors and to choose male donors for male recipients in HLA-identical related donor SCT... - Trisomy 8 in an allogeneic stem cell transplant recipient representative of a donor-derived constitutional abnormalityNoelle V Frey
Division of Hematology Oncology and Abramson Cancer Center, Hospital of University of Pennsylvania, Philadelphia, Pennsylvania, USA
Am J Hematol 83:846-9. 2008..The case illustrates the importance of identifying donor-derived constitutional abnormalities to avoid the assumption that these cytogenetic abnormalities after HSCT are representative of malignant disease... - Graft-versus-host disease after donor leukocyte infusions: presentation and managementNoelle V Frey
Division of Hematology Oncology and Abramson Cancer Center, University of Pennsylvania Medical Center, 16 Penn Tower, 3400 ISpruce St, Philadelphia PA 19106, USA
Best Pract Res Clin Haematol 21:205-22. 2008.... - Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantationA W Loren
Bone Marrow and Stem Cell Transplant Programs, University of Pennsylvania Cancer Center, Philadelphia, PA, USA
Bone Marrow Transplant 35:921-6. 2005..05). The combination of Cs/MMF is inadequate GVHD prophylaxis for UD-NST. The use of Cs, MTX, and alemtuzumab eliminated severe acute GVHD; its impact on response merits further study... - Unrelated donor leukocyte infusions to treat relapse after unrelated donor bone marrow transplantationJose Leis
Bone Marrow and Stem Cell Transplant Program, Oregon Health Sciences University, Portland, USA
Leuk Lymphoma 43:9-17. 2002.... - Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibodyDonald E Tsai
Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Cancer Center, Philadelphia, 19104, USA
Clin Lymphoma 4:56-9. 2003..This case report demonstrates the potential for repeated treatments with radioimmunotherapy agents in patients with chemotherapy-refractory non-Hodgkin's lymphoma... - Functional unresponsiveness and replicative senescence of myeloid leukemia antigen-specific CD8+ T cells after allogeneic stem cell transplantationGregory L Beatty
Abramson Family Cancer Research Institute, Abramson Cancer Center, Department of Pathology and Laboratory Medicine, Division of Hematology Oncology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Clin Cancer Res 15:4944-53. 2009..CD8(+) T-cell responses to MHC class I-restricted tumor epitopes, not just allogeneic antigens, may help mediate antileukemia effects after HSCT, but the specificity and function of such cells are not completely understood... - Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiationDan T Vogl
Abramson Cancer Center, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA, 19104, USA
Leuk Lymphoma 46:1313-20. 2005..Physicians should be aware of the potential for developing a gemcitabine-induced radiation recall reaction resulting in hemodynamically significant pericardial effusion... - Nonmyeloablative allogeneic stem cell transplantation for refractory Hodgkin's lymphoma complicated by interleukin-2 responsive progressive multifocal leukoencephalopathyR J Buckanovich
Bone Marrow and Stem Cell Transplant Program, Division of Hematology-Oncology and Department of Medicine, University of Pennsylvania Medical Center, 16 Penn Tower, 3400 Spruce Street, Philadelphia 19104, USA
Ann Hematol 81:410-3. 2002..However, it demonstrates the potential for severe complications related to immunosuppression, especially in heavily pretreated patients. The toxicity after NMASCT should not be understated and will need to be explored further... - Donor leukocyte infusions in acute myelogenous leukemiaD L Porter
Bone Marrow and Stem Cell Transplant Program, Hematology/Oncology Division, 16 Penn Tower, University of Pennsylvania Medical Center, 3400 Spruce Street, Philadelphia, PA 19104, USA
Leukemia 17:1035-7. 2003 - Umbilical cord blood xenografts in immunodeficient mice reveal that T cells enhance hematopoietic engraftment beyond overcoming immune barriers by stimulating stem cell differentiationElizabeth O Hexner
Division of Hematology Oncology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Biol Blood Marrow Transplant 13:1135-44. 2007..CD3/CD28 costimulation of UCB T cells represents a potential strategy for enhancing the engraftment of UCB... - Cutaneous Hodgkin's diseaseCamille E Introcaso
Department of Dermatology, The University of Pennsylvania, Philadelphia, USA
J Am Acad Dermatol 58:295-8. 2008..A review of the literature demonstrates that the patient's lesion morphology and distribution are typical of specific manifestations of cutaneous Hodgkin's disease... - Homocysteine and prothrombin fragment 1+2 levels in patients with veno-occlusive disease after stem cell transplantationJohn Gerecitano
Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104, USA
J Hematother Stem Cell Res 12:215-23. 2003.... - A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemiaDonald E Tsai
Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
Clin Cancer Res 14:5619-25. 2008..We therefore conducted a phase I dose escalation study to assess the maximum tolerated dose, toxicities, and activity of bexarotene in patients with non-M3 acute myeloid leukemia (AML)... - Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantationA W Loren
Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA 19104, USA
Bone Marrow Transplant 41:483-93. 2008..This review discusses the rationale, biology, complications and future applications of DLI in acute leukemia patients after allogeneic SCT... - Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(★)R Reshef
Abramson Cancer Center Department of Biostatistics and Epidemiology Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Am J Transplant 11:336-47. 2011..Patients with none or one of these factors had a 3-year overall survival of 100% and 79%, respectively. These findings support the use of RI alone in low-risk PTLD and suggest factors that predict response and survival... - Cycles of dose-intensive chemotherapy with peripheral stem cell support in persistent or recurrent platinum-sensitive ovarian cancerM A Morgan
Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Medical Center, Philadelphia 19104, USA
Gynecol Oncol 67:272-6. 1997..The objective was to determine the toxicity and surgically documented response rate of sequential high-dose chemotherapy with peripheral stem cell support in patients with persistent or recurrent cisplatin-sensitive ovarian cancer... - Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusionsD L Porter
Division of Hematology Oncology, Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
Blood 95:1214-21. 2000..UDLI is an acceptable alternative to other treatment options for relapse after unrelated donor BMT. (Blood. 2000;95:1214-1221).. - Stem cell transplantation for metastatic breast cancer: analysis of tumor contaminationE A Stadtmauer
Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Cancer Center, Philadelphia 19104, USA
Med Oncol 16:279-88. 1999.... - Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignanciesD L Porter
Division of Hematology Oncology, Department of Medicine, University of Pennsylvania Medical Center, Philadelphia 19104, USA
J Clin Oncol 17:1234. 1999.... - Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphomaC Andreadis
Bone Marrow and Stem Cell Transplantation Program and Lymphoma Program, The Abramson Cancer Center, University of Pennsylvania, 16 Penn Tower, 3400 Spruce Street, Philadelphia, 19104, USA
Bone Marrow Transplant 36:955-61. 2005..ASCT is thus a safe therapeutic approach in FL, resulting in long-term EFS and OS for some patients, even with transformed disease... - Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patientsD E Tsai
Hematologic Malignancies Program, University of Pennsylvania Cancer Center, Philadelphia 19104, USA
Transplantation 71:1076-88. 2001..With the increased use of organ transplantation and intensive immunosuppression, this disease is becoming more common. We explore reduction in immunosuppression as an initial therapy for PTLD... - The graft-versus-leukemia effects of allogeneic cell therapyD L Porter
Division of Hematology Oncology, University of Pennsylvania Medical Center, Philadelphia 19104, USA
Annu Rev Med 50:369-86. 1999.... - Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantationJ Svoboda
Bone Marrow and Stem Cell Transplant Program, Abramson Cancer Center of University of Pennsylvania, Philadelphia, PA 19104, USA
Bone Marrow Transplant 38:211-6. 2006..A positive FDG-PET scan after salvage chemotherapy and prior ASCT indicates an extremely poor chance of durable response after ASCT... - Novel approaches to allogeneic stem cell therapyV Bhatia
Bone Marrow and Stem Cell Transplant Program, Hematology-Oncology Division, Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, PA, USA
Expert Opin Biol Ther 1:3-15. 2001..In addition, the durability of response is unknown. Nevertheless, the use of non-myeloablative conditioning and ACT may provide a new paradigm for allogeneic cell transplantation and the immunotherapy of cancer... - 'GVHD': graft-versus-host disease or graft-versus-Hodgkin's disease? An old acronym with new meaningD L Porter
Bone Marrow and Stem Cell Transplant Program, Division of Hematology Oncology, University of Pennsylvania Medical Center, Philadelphia 19104, USA
Bone Marrow Transplant 31:739-46. 2003..Nonmyeloablative conditioning and allogeneic SCT may induce a direct GVHL reaction with less conditioning regimen-related toxicity and ultimately may have the potential to improve cure rates and survival for advanced HL patients... - Second auto-SCT is safe and effective salvage therapy for relapsed multiple myelomaR L Olin
Bone Marrow and Stem Cell Transplant Program, Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Bone Marrow Transplant 43:417-22. 2009..We conclude that in well-selected patients, salvage auto-SCT is safe and effective for relapsed myeloma... - Do simultaneous bilateral tunneled infusion catheters in patients undergoing bone marrow transplantation increase catheter-related complications?Lauren J Kaufman
Department of Radiology, Division of Interventional Radiology and Medicine, University of Pennsylvania Medical Center, 1 Silverstein, 3400 Spruce Street, Philadelphia, PA 19104, USA
J Vasc Interv Radiol 15:57-61. 2004.... - Chimeric Antigen Receptor Therapy for B-cell MalignanciesDavid L Porter
1 Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, 19104, USA
J Cancer 2:331-2. 2011.... - Circulating osteogenic precursor cells in heterotopic bone formationRobin K Suda
Department of Medicine, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania 19104 6160, USA
Stem Cells 27:2209-19. 2009..Thus, bone formation is not limited to cells of the mesenchymal lineage, and circulating cells of hematopoietic origin can also serve as osteogenic precursors at remote sites of tissue inflammation... - Umbilical cord blood transplantation: where do we stand?Raymond C Wadlow
Bone Marrow and Stem Cell Transplant Program, Hematology Oncology Division, Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA
Biol Blood Marrow Transplant 8:637-47. 2002..This overview examines the advantages and disadvantages of UCB as a donor source and reviews data from preclinical and clinical studies. Ethical issues regarding UCB transplantation are also addressed... - Hypertriglyceridemia presenting as "pink blood" and elevated hemoglobin levelDonald E Tsai
Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA
Am J Hematol 83:253. 2008 - Post-transplant lymphoproliferative disorder: a reviewA W Loren
Hematologic Malignancies Program, University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA
Bone Marrow Transplant 31:145-55. 2003.... - Use of EBV PCR for the diagnosis and monitoring of post-transplant lymphoproliferative disorder in adult solid organ transplant patientsDonald E Tsai
Hematologic Malignancies Program, University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania 19104, USA
Am J Transplant 2:946-54. 2002..We conclude that peripheral blood EBV PCR may have a role in the diagnosis and monitoring of post-transplant lymphoproliferative disorder in adult solid organ transplant patients... - Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive diseaseA D Cohen
Hematologic Malignancies Program and the Bone Marrow and Stem Cell Transplantation Program, University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA
Bone Marrow Transplant 30:23-8. 2002..The other seven patients did not meet diagnostic criteria for VOD. We conclude that GO can be safe and effective in patients who relapse following HSCT, but that caution is warranted in patients with multiple risk factors for VOD... - Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantationJohn E Levine
University of Michigan, Ann Arbor, MI, USA
J Clin Oncol 20:405-12. 2002..A chemotherapy strategy was used to debulk disease before administration of granulocyte colony-stimulating factor (G-CSF)-primed DLIs... - Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transferAaron P Rapoport
University of Maryland Greenebaum Cancer Center and Center for Vaccine Development, 22 South Greene Street Baltimore, Maryland 21201, USA
Nat Med 11:1230-7. 2005..05). In the setting of lymphopenia, combined vaccine therapy and adoptive T-cell transfer fosters the development of enhanced memory T-cell responses...
Research Grants
- Mid-career investigator award in allogeneic adoptive immunotherapyDavid Porter; Fiscal Year: 2007....